SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been developed as a new therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), which can inhibit the proximal renal tubular SGLT protein family reabsorption of glucose, thereby reducing blood sugar levels (Chao and Henry, 2010).